Abstract
Tamoxifen, a selective oestrogen receptor modulator, has been used in the treatment of all stages of hormone-responsive breast cancer. However, tamoxifen shows partial oestrogenic activity in the uterus and its use has been associated with an increased incidence of endometrial cancer. The molecular explanation for these observations is not known. Here we show that tamoxifen and oestrogen have distinct but overlapping target gene profiles. Among the overlapping target genes, we identify a paired-box gene, PAX2, that is crucially involved in cell proliferation and carcinogenesis in the endometrium. Our experiments show that PAX2 is activated by oestrogen and tamoxifen in endometrial carcinomas but not in normal endometrium, and that this activation is associated with cancer-linked hypomethylation of the PAX2 promoter.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371–1388 (1998)
Jordan, V. C., Gapstur, S. & Morrow, M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J. Natl Cancer Inst. 93, 1449–1457 (2001)
Persson, I. Estrogens in the causation of breast, endometrial and ovarian cancers—evidence and hypotheses from epidemiological findings. J. Steroid Biochem. Mol. Biol. 74, 357–364 (2000)
Akhmedkhanov, A., Zeleniuch-Jacquotte, A. & Toniolo, P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann. NY Acad. Sci. 943, 296–315 (2001)
Hernandez, E. Endometrial adenocarcinoma: a primer for the generalist. Obstet. Gynecol. Clin. North Am. 28, 743–757 (2001)
Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927–937 (1998)
Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997)
Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465–2468 (2002)
Lin, C. Y. et al. Discovery of estrogen receptor α target genes and response elements in breast tumour cells. Genome Biol. 5, R66 (2004)
O'Lone, R., Frith, M. C., Karlsson, E. K. & Hansen, U. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 18, 1859–1875 (2004)
Wang, D. Y., Fulthorpe, R., Liss, S. N. & Edwards, E. A. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol. Endocrinol. 18, 402–411 (2004)
Seth, P., Krop, I., Porter, D. & Polyak, K. Novel estrogen and tamoxifen induced genes identified by SAGE (serial analysis of gene expression). Oncogene 21, 836–843 (2002)
Ghosh, M. G., Thompson, D. A. & Weigel, R. J. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res. 60, 6367–6375 (2000)
Dardes, R. C. et al. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol. Oncol. 85, 498–506 (2002)
Farnell, Y. Z. & Ing, N. H. The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells. J. Steroid Biochem. Mol. Biol. 84, 453–461 (2003)
Sakamoto, T. et al. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol. Cell. Endocrinol. 192, 93–104 (2002)
Wang, Z. et al. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene 21, 3517–3524 (2002)
Nishida, M. The Ishikawa cells from birth to the present. Hum. Cell 15, 104–117 (2002)
Stayner, C. K., Cunliffe, H. E., Ward, T. A. & Eccles, M. R. Cloning and characterization of the human PAX2 promoter. J. Biol. Chem. 273, 25472–25479 (1998)
Shyamala, G. & Guiot, M. C. Activation of κB-specific proteins by estradiol. Proc. Natl Acad. Sci. USA 89, 10628–10632 (1992)
Galien, R., Evans, H. F. & Garcia, T. Involvement of CCAAT/enhancer-binding protein and nuclear factor-κB binding sites in interleukin-6 promoter inhibition by estrogens. Mol. Endocrinol. 10, 713–722 (1996)
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A. & Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843–852 (2000)
Zhang, H. et al. Differential gene regulation by the SRC family of coactivators. Genes Dev. 18, 1753–1765 (2004)
Cho, K. S., Elizondo, L. I. & Boerkoel, C. F. Advances in chromatin remodeling and human disease. Curr. Opin. Genet. Dev. 14, 308–315 (2004)
Watanabe, T. et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors α and β. Biochem. Biophys. Res. Commun. 236, 140–145 (1997)
Robertson, J. A., Bhattacharyya, S. & Ing, N. H. Tamoxifen up-regulates oestrogen receptor-α, c-fos and glyceraldehyde 3-phosphate-dehydrogenase mRNAs in ovine endometrium. J. Steroid Biochem. Mol. Biol. 67, 285–292 (1998)
Jones, P. S., Parrott, E. & White, I. N. Activation of transcription by estrogen receptor α and β is cell type- and promoter-dependent. J. Biol. Chem. 274, 32008–32014 (1999)
Russo, L. A., Calabro, S. P., Filler, T. A., Carey, D. J. & Gardner, R. M. In vivo regulation of syndecan-3 expression in the rat uterus by 17β-estradiol. J. Biol. Chem. 276, 686–692 (2001)
Hague, S. et al. Tamoxifen induction of angiogenic factor expression in endometrium. Br. J. Cancer 86, 761–767 (2002)
Castro-Rivera, E. & Safe, S. 17β-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context. J. Steroid Biochem. Mol. Biol. 84, 23–31 (2003)
Bramlett, K. S. & Burris, T. P. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. J. Steroid Biochem. Mol. Biol. 86, 27–34 (2003)
Paech, K. et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277, 1508–1510 (1997)
Webb, P., Nguyen, P. & Kushner, P. J. Differential SERM effects on corepressor binding dictate ERα activity in vivo. J. Biol. Chem. 278, 6912–6920 (2003)
Klotz, D. M., Hewitt, S. C., Korach, K. S. & Diaugustine, R. P. Activation of a uterine insulin-like growth factor I signalling pathway by clinical and environmental estrogens: requirement of estrogen receptor-α. Endocrinology 141, 3430–3439 (2000)
Jepsen, K. et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102, 753–763 (2000)
Katzenellenbogen, B. S. et al. Antiestrogens: mechanisms and actions in target cells. J. Steroid Biochem. Mol. Biol. 53, 387–393 (1995)
Montano, M. M., Muller, V., Trobaugh, A. & Katzenellenbogen, B. S. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol. 9, 814–825 (1995)
Maulbecker, C. C. & Gruss, P. The oncogenic potential of Pax genes. EMBO J. 12, 2361–2367 (1993)
Silberstein, G. B., Dressler, G. R. & Van Horn, K. Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 21, 1009–1016 (2002)
Khoubehi, B. et al. Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J. Urol. 165, 2115–2120 (2001)
Dressler, G. R. & Douglass, E. C. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumour. Proc. Natl Acad. Sci. USA 89, 1179–1183 (1992)
Muratovska, A., Zhou, C., He, S., Goodyer, P. & Eccles, M. R. Paired-box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22, 7989–7997 (2003)
Feinberg, A. P. & Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89–92 (1983)
Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nature Rev. Cancer 4, 143–153 (2004)
Gupta, A., Godwin, A. K., Vanderveer, L., Lu, A. & Liu, J. Hypomethylation of the synuclein γ gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 63, 664–673 (2003)
Nishigaki, M. et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 65, 2115–2124 (2005)
Sato, N. et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 63, 4158–4166 (2003)
Acknowledgements
We thank J. Green for editorial assistance. This work was supported by grants from the National Natural Science Foundation of China and from the ‘863 Program’ and the ‘973 Program’ of the Ministry of Science and Technology of China (to Y.S.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The microarray data are deposited in the Gene Expression Omnibus under accession number GSE3013. Reprints and permissions information is available at npg.nature.com/reprintsandpermissions. The authors declare no competing financial interests.
Supplementary information
Supplementary Data
The MIAME checklist. (DOC 335 kb)
Supplementary Figures
This file contains Supplementary Figures 1–6. (PPT 6821 kb)
Supplementary Methods
This file contains further descriptions of the methods used in this study and additional references. (DOC 74 kb)
Rights and permissions
About this article
Cite this article
Wu, H., Chen, Y., Liang, J. et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438, 981–987 (2005). https://doi.org/10.1038/nature04225
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature04225
This article is cited by
-
NFIB facilitates replication licensing by acting as a genome organizer
Nature Communications (2023)
-
Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5
Cell Death Discovery (2022)
-
Kidney-Derived Methylated PAX2 Sequences in the Urine of Healthy Subjects as a Convenient Model for Optimizing Methylation-Based Liquid biopsy
Molecular Biotechnology (2022)
-
Estrogen-ERα signaling and DNA hypomethylation co-regulate expression of stem cell protein PIWIL1 in ERα-positive endometrial cancer cells
Cell Communication and Signaling (2020)
-
Expression of PAX2 and PTEN in Oestrogen-Driven Endometrial Hyperplasia and Neoplasia
Indian Journal of Gynecologic Oncology (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.